Humacyte share price logo

Humacyte

NASDAQ: HUMA

$0.57

-0.03

(-5.15%)

as on

Humacyte Stock Performance

as on September 2, 2026 at 2:16 pm IST

  • Day's High

    $0.57
    $0.60

    5.26%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.53
    $2.55
    downward going graph

    7.70%

    Downside

    347.37%

    Upside

    downward going graph

Humacyte share price movements today

Previous Close
$0.60
Open
$0.60
Volume
14.6M
Market Cap
$167.1M
Day's Low - High
$0.57 - $0.60
52 Week Low - High
$0.53 - $2.55

Humacyte Historical Returns

1 Month Return
-12.7 %
3 Month Return
-58.96 %
1 Year Return
-62.23 %
3 Year Return
-85.88 %
5 Year Return
-96.42 %

Humacyte Stock Fundamentals & Key Indicators

Check Humacyte market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$167.1M

EPS (TTM)

-0.4

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-103.2M

Revenue (TTM)

2.1M

Profit Margin

0.00%

Return On Equity TTM

-547.87%

Humacyte vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Humacyte with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$167.1M-96.42%NA0.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$137.9B174.9%31.9286.04%NA
BUY$61.6B-61.21%-7.98-12.57%NA
BUY$82.3B21.91%19.984.86%0.44%

Stock Returns calculator for Humacyte Stock including INR - Dollar returns

The Humacyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Humacyte investment value today

Current value as on today

₹40,725

Returns

-₹59,275

(-59.28%)

Returns from Humacyte Stock

-₹62,252 (-62.25%)

Dollar Impact

₹2,977 (+2.98%)

Analyst Recommendation on Humacyte Stock

Based on 5 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 5 analysts, 80% of analysts recommend a 'BUY' rating for Humacyte. Average target price of $1.85

Humacyte Share Price Target

Get share price movements and forecasts by analysts on Humacyte.

What analysts predicted

69.19%UPSIDE

Target Price

$1.85

Current Price

$0.57

Analyzed by

5 Analysts

Target

$1.85

Humacyte target price $1.85, a slight upside of 69.19% compared to current price of $0.57. According to 5 analysts rating.

Indian Investors' Interest in Humacyte Stock

Search interest for Humacyte Stock has increased by 78% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:78% versus previous 30 day period

Humacyte Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
7
0
0
0
0
0
0
Gross Profit
-1
-1
-1
3
-1
-1
-1
-10
-1
0
Operating Income
-26
-29
-30
-28
-23
-29
-24
-30
-28
-26
EBITDA
-28
-52
-34
-16
43
-33
-13
-19
-13
-33
Interest Expense
1
2
2
2
3
2
2
3
2
2
Depreciation
1
1
1
1
1
1
1
1
1
-
Income Before Tax
-31
-56
-39
-20
39
-37
-17
-24
-17
-36
Income Tax Expense
1
-
-
-1
-
-
-
-
-
-
Net Income
-31
-56
-39
-20
39
-37
-17
-24
-17
-36
Net Profit Margin
0.00%
0.00%
0.00%
-289.71%
7570.41%
-12510.96%
-2325.37%
-5311.35%
-3559.39%
-9064.53%

Humacyte Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
6
1
1
1
-
-
2
Gross Profit
-69
-52
-60
-6
-76
-7
-15
Operating Income
-85
-64
-81
-84
-100
-114
-107
EBITDA
-78
-56
-13
2
-96
-132
-22
Interest Expense
2
2
4
6
6
9
11
Depreciation
-
8
8
8
8
7
7
Income Before Tax
-85
-66
-26
-11
-110
-148
-40
Income Tax Expense
-
2
-64
-76
3
-
-
Net Income
-85
-66
-26
-11
-110
-148
-40
Net Profit Margin
-1380.67%
-4461.70%
-2096.36%
-764.54%
0.00%
0.00%
-2003.58%

Humacyte Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-56
-39
-20
39
-37
-17
-24
-17
-36
Operating Cash Flow
-21
-22
-26
-28
-26
-23
-26
-25
-22
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
0
0
51
46
2
-44
57
23
53
Change in Cash
-21
-22
24
17
-24
-68
31
-1
31

Humacyte Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-66
-26
-11
-110
-148
-40
Operating Cash Flow
-55
-81
-71
-73
-98
-105
Investing Cash Flow
0
-8
4
0
-1
0
Financing Cash Flow
2
266
-1
4
114
61
Change in Cash
39
177
-67
-69
14
-44

Mutual Funds that own Humacyte Stock

Check out the Mutual Funds with significant holdings in Humacyte.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
2.518187%
6995476
Fidelity Salem Street Trust
0.645568%
1793378
Fidelity Concord Street Trust
0.409332%
1137118
VANGUARD SCOTTSDALE FUNDS
0.322875%
896941
SCHWAB CAPITAL TRUST
0.172932%
480404

Global Institutional Holdings in Humacyte

Funds
Holdings
Vanguard
3.75%
Jacob Mitchell
3.64%
iShares
0.78%
Schwab
0.34%
David Costen Haley
0.28%

Humacyte News & Key Events

  • img

    Today's Timeline - 09 February

    Mon, 06:30 PM

    -

    Humacyte announces DoD funding for biologic vascular repair technologies in traumatic injuries, enhancing support for its bioengineered blood vessels.

Insights on Humacyte

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 37.1% return, outperforming this stock by 123.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 537.7% return, outperforming this stock by 599.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -17.61M → -36.80M (in $), with an average decrease of 108.9% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, HUMA stock has moved down by -16.3%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 495.0K → 406.0K (in $), with an average decrease of 18.0% per quarter

About Humacyte

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
OrganisationHumacyte
Headquarters2525 East North Carolina Highway 54, Durham, NC, United States, 27713
IndustryBiotechnology
CEODr. Laura E. Niklason M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Humacyte

Name

Title

Dr. Heather Connelly Ph.D.

Chief Quality & Regulatory Officer

Mr. Rick McElheny

Senior Vice President of Business Development

Mr. Jim Mercadante

Chief Commercial Officer

Dr. Todd E. Rasmussen M.D.

Chief Surgical Officer

Mr. Dale A. Sander

CFO, Chief Corporate Development Officer & Treasurer

Dr. Shamik J. Parikh M.D.

Chief Medical Officer

Ms. Sabrina Osborne GPHR, SPHR

Chief People Officer

Ms. Lisa Molyneux

Chief Strategy Officer

Dr. Laura E. Niklason M.D., Ph.D.

Founder, President, CEO & Director

FAQs

What is Humacyte share price today?

Humacyte share price today is $0.57 as on at the close of the market. Humacyte share today touched a day high of $0.60 and a low of $0.57.

What is the 52 week high and 52 week low for Humacyte share?

Humacyte share touched a 52 week high of $2.55 on and a 52 week low of $0.53 on . Humacyte stock price today i.e. is closed at $0.57,which is 77.65% down from its 52 week high and 8.34% up from its 52 week low.

What is Humacyte's market capitalisation today?

Humacyte market capitalisation is $0.00T as on .

How to invest in Humacyte Stock (HUMA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Humacyte on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Humacyte Shares that will get you 2.6316 shares as per Humacyte share price of $0.57 per share as on September 2, 2026 at 8:46 am IST.

What is the minimum amount required to buy Humacyte Stock (HUMA) from India?

Indian investors can start investing in Humacyte (HUMA) shares with as little as ₹94.94 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Humacyte stock (as per the Rupee-Dollar exchange rate as on ). Based on Humacyte share’s latest price of $0.57 as on September 2, 2026 at 8:46 am IST, you will get 17.5439 shares of Humacyte. Learn more about fractional shares .

What are the returns that Humacyte has given to Indian investors in the last 5 years?

Humacyte stock has given -96.42% share price returns and 30.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?